Identifikation og håndtering af barrierer for tilbageholdelse i livmoderhalskræftbehandlingskaskaden blandt kvinder med hiv i Sydafrika
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Forenede Stater, 02215
- Boston University
-
-
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Sydafrika, 4000
- MatCH Research Unit (MRU), a Division of the Wits Health Consortium, University of Witwatersrand
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier:
- At have livmoderhals
- I alderen 18+
- At leve med HIV
- Seneste højrisiko unormale Pap-resultater inden for den sidste måned (hvis det er nødvendigt, kan vi øge intervallet med op til 6 måneder for at sikre, at vi når vores mål).
Ekskluderingskriterier:
- yngre end 18 år
- HIV-negativ
- Ingen livmoderhals/historie om hysterektomi
- Nylige normale eller lavrisiko unormale Pap-resultater
- Ude af stand til at give informeret samtykke eller samtykke på engelsk eller isiZulu og/eller har en betydelig psykiatrisk sygdom (f.eks. aktiv psykotisk lidelse eller ubehandlet bipolar lidelse), der kan forstyrre deltagelse, vil blive udelukket. Potentielle deltagere vil også blive spurgt, om de har helbredsmæssige forhold, der gør det svært for dem at rejse til klinikken.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Participant intervention
The intervention group will consist of two sessions, conducted in-person, coupled with text-based client navigation.The intervention group will complete three major assessments: baseline (T1), at the conclusion of the intervention (T2), and a three-month follow-up (T3).
Until the follow-up assessment, the interventionist will send participants 2-3 SMS messages (one-way) per month.
The content of these messages will be developed collaboratively between the participant and the interventionist during each session; messages could include reminders about follow-ups and/or prompts to use new skills and resources for navigating specific barriers.
|
The participant intervention will be two sessions, conducted in-person, coupled with text-based client navigation with women who received a recent Pap smear test.
The intervention integrates (1) information to improve awareness of cervical cancer susceptibility and treatment, (2) brief cognitive behavioral therapy (CBT) skills to reduce individual-level barriers, (3) problem-solving to increase social support, and (4) patient navigation tools to mitigate clinic-level challenges.
|
|
Ingen indgriben: Enhanced treatment as usual
The enhanced treatment as usual (ETAU) group will receive treatment as usual, including being notified of their Pap results and instructed to set up a follow-up appointment if needed, as is typical in routine care.
They will additionally receive an information sheet describing Pap smears and the relationship between HIV, HPV, and cervical cancer.
The ETAU group will complete the T1, T2, and T3 assessments.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility of the intervention
Tidsramme: About 1 month after the start of intervention and at about 3 months after the start of the intervention
|
Feasibility will be demonstrated if all three are met by participants: (1) 50% of participants who are approached choose to enroll; (2) 70% of participants complete the intervention; and (3) 60% complete the 3-month follow-up.
Feasibility of the implementation of the intervention will be explored in interviews with providers and clinic staff.
To assess fidelity, each intervention session with be audio recorded; an assessor will review 20% of the session transcripts and determine whether all key session themes were addressed using checklists developed by the study team for the intervention.
|
About 1 month after the start of intervention and at about 3 months after the start of the intervention
|
|
Acceptability of the intervention
Tidsramme: About 1 month after the start of intervention and at about 3 months after the start of the intervention
|
Acceptability will be measured using the seven component constructs of the acceptability of health care interventions framework using a five-point Likert style scale.
The seven components include affective attitude (i.e., how an individual feels about the intervention), burden, ethicality (i.e., the extent to which the intervention aligns with one's value system), intervention coherence, opportunity costs, perceived effectiveness, and self-efficacy.
Acceptability will be demonstrated if, on average, at least 75% of the participants rate five or more of the items on the eight-item Acceptability of Healthcare Interventions Questionnaire with a 4 or a 5 on the Likert-style scale.
Acceptability of the intervention will also be explored in interviews with providers, clinic staff, interventionalists, and other relevant stakeholders.
|
About 1 month after the start of intervention and at about 3 months after the start of the intervention
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Follow-up appointment attendance
Tidsramme: about 1 month after the start of intervention and about 3 months after the start of the intervention
|
This will be measured by comparing the proportions between intervention and ETAU groups at the end of the intervention and the three-month follow-up visit.
|
about 1 month after the start of intervention and about 3 months after the start of the intervention
|
|
Self-efficacy to attend cervical cancer-related health care appointment
Tidsramme: At the start of the intervention, about 1 month after the start of intervention, and at about 3 months after the start of the intervention
|
This will be measured by comparing change in scores from baseline, post-intervention, and the three-month follow-up visit between the intervention and ETAU groups.
The maximum score is 35 and the minimum score is 7, with higher scores indicating more self-efficacy.
|
At the start of the intervention, about 1 month after the start of intervention, and at about 3 months after the start of the intervention
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Amelia Stanton, PhD, Boston University Charles River Campus
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Blodbårne infektioner
- Urogenitale sygdomme
- Genitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Sygdomme i immunsystemet
- Infektioner
- RNA-virusinfektioner
- Virussygdomme
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Genitale neoplasmer, kvindelige
- Langsomme virussygdomme
- Livmoderhalssygdomme
- Uterine neoplasmer
- HIV-infektioner
- Erhvervet immundefektsyndrom
- Uterine cervikale neoplasmer
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 7356E
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .